Red Blood Cell Membrane Spontaneously Coated Nanoprodrug Based on Phosphatidylserine for Antiatherosclerosis Applications

• Published in: ACS applied materials & interfaces 2024-09, Vol.16 (35), p.46578-46589
• Main Authors: Cao, Yu, Han, ZhiQiang, Zhu, Li, He, Zhigui, Mou, Nianlian, Duan, Xinmei, Chen, Qiao, Qin, Xian, Zhang, Kun, Qu, Kai, Zhong, Yuan, Wu, Wei
• Format: Article
• Language: English
• Subjects: atherosclerosis; biocompatibility; biomimetics; brain; disease progression; drug therapy; drugs; erythrocyte membrane; etiology; Functional Nanostructured Materials (including low-D carbon); heart; nanomedicine; phagocytes; phosphatidylserines; polypeptides; toxicity
• ISSN: 1944-8244; 1944-8252; 1944-8252
• DOI: 10.1021/acsami.4c07720

Atherosclerosis (AS) is characterized by the accumulation of lipids within the walls of coronary arteries, leading to arterial narrowing and hardening. It serves as the primary etiology and pathological basis for cardiovascular diseases affecting the heart and brain. However, conventional pharmacotherapy is constrained by inadequate drug delivery and pronounced toxic side effects. Moreover, the inefficacy of nanomedicine delivery systems in controlling disease progression may be attributed to nonspecific clearance by the mononuclear phagocyte system. Thus, a biomimetic platform spontaneously enveloped by red blood cell membrane is exploited for anti-atherosclerosis applications, offering favorable biocompatibility. The CLIKKPF polypeptide is introduced to develop red blood cell membrane spontaneously encapsulated nanotherapeutics only through simple coincubation. Given the functional modifications, RBC@P-LVTNPs is beneficial to facilitate the target drug delivery to the atherosclerotic lesion, responding precisely to the pathological ROS accumulation, thereby accelerating the on-demand drug release. Both in vivo and in vitro results also confirm the significant therapeutic efficacy and favorable biocompatibility of the biomimetic nanomedicine delivery system, thus providing a promising candidate for nanotherapeutics against AS.